Operates a pharmaceutical direct sales business through online stores on Tmall.com and offline pharmacy outlets. Now — the numbers.
This is an established company with proven profits.
Average growth of 13% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $1.6B would still be left in the vault — a solid cushion for hard times.
The market pays 23.2× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 75% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 13% a year on average.
There is $1.6B in the vault; even if every debt were paid off, $1.6B would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
The stock sits at $0.40. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.